KR102984130B1 - B 세포 악성 종양을 치료하기 위한 아칼라브루티닙 및 카피바세르팁의 치료 조합 - Google Patents

B 세포 악성 종양을 치료하기 위한 아칼라브루티닙 및 카피바세르팁의 치료 조합

Info

Publication number
KR102984130B1
KR102984130B1 KR1020227018891A KR20227018891A KR102984130B1 KR 102984130 B1 KR102984130 B1 KR 102984130B1 KR 1020227018891 A KR1020227018891 A KR 1020227018891A KR 20227018891 A KR20227018891 A KR 20227018891A KR 102984130 B1 KR102984130 B1 KR 102984130B1
Authority
KR
South Korea
Prior art keywords
capivasertip
administered
acalabrutinib
another embodiment
dosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227018891A
Other languages
English (en)
Korean (ko)
Other versions
KR20220098175A (ko
Inventor
한나 드라이
브랜든 윌리스
앤드류 블뢰허
제롬 메테탈
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20220098175A publication Critical patent/KR20220098175A/ko
Application granted granted Critical
Publication of KR102984130B1 publication Critical patent/KR102984130B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227018891A 2019-11-04 2020-10-30 B 세포 악성 종양을 치료하기 위한 아칼라브루티닙 및 카피바세르팁의 치료 조합 Active KR102984130B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930208P 2019-11-04 2019-11-04
US62/930,208 2019-11-04
PCT/EP2020/080493 WO2021089419A1 (en) 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Publications (2)

Publication Number Publication Date
KR20220098175A KR20220098175A (ko) 2022-07-11
KR102984130B1 true KR102984130B1 (ko) 2026-07-01

Family

ID=73043259

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018891A Active KR102984130B1 (ko) 2019-11-04 2020-10-30 B 세포 악성 종양을 치료하기 위한 아칼라브루티닙 및 카피바세르팁의 치료 조합

Country Status (14)

Country Link
US (1) US12691113B2 (cg-RX-API-DMAC7.html)
EP (1) EP4054582B1 (cg-RX-API-DMAC7.html)
JP (1) JP7575454B2 (cg-RX-API-DMAC7.html)
KR (1) KR102984130B1 (cg-RX-API-DMAC7.html)
CN (1) CN114728003B (cg-RX-API-DMAC7.html)
AU (1) AU2020381240C1 (cg-RX-API-DMAC7.html)
CA (1) CA3158321A1 (cg-RX-API-DMAC7.html)
DK (1) DK4054582T3 (cg-RX-API-DMAC7.html)
ES (1) ES3055126T3 (cg-RX-API-DMAC7.html)
FI (1) FI4054582T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022005250A (cg-RX-API-DMAC7.html)
PL (1) PL4054582T3 (cg-RX-API-DMAC7.html)
PT (1) PT4054582T (cg-RX-API-DMAC7.html)
WO (1) WO2021089419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024104561A1 (en) * 2022-11-15 2024-05-23 Astrazeneca Ab Therapeutic combinations of capivasertib and venetoclax

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
AU2014360537B2 (en) * 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
EP3076974A1 (en) * 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
JP6785804B2 (ja) * 2015-06-23 2020-11-18 ギリアド サイエンシズ, インコーポレイテッド B細胞悪性腫瘍を治療するための組合せ療法
US20170071962A1 (en) 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
BR112017002594A2 (pt) * 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
AU2018335617B2 (en) * 2017-09-25 2021-12-09 Astrazeneca Ab Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
KR20250119664A (ko) 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, Vol. 130, No. 3, pp. 310-322 (2017)*
JOURNAL OF HEMATOLOGY & ONCOLOGY, Vol. 9, No. 1, pp. 1-4 (2016)*

Also Published As

Publication number Publication date
JP7575454B2 (ja) 2024-10-29
JP2023501317A (ja) 2023-01-18
PL4054582T3 (pl) 2026-02-16
EP4054582B1 (en) 2025-09-03
FI4054582T3 (fi) 2025-12-04
CA3158321A1 (en) 2021-05-14
KR20220098175A (ko) 2022-07-11
EP4054582A1 (en) 2022-09-14
DK4054582T3 (da) 2025-12-01
PT4054582T (pt) 2025-12-10
AU2020381240C1 (en) 2024-02-15
WO2021089419A1 (en) 2021-05-14
AU2020381240A1 (en) 2022-06-23
US20220401442A1 (en) 2022-12-22
CN114728003A (zh) 2022-07-08
US12691113B2 (en) 2026-07-28
AU2020381240B2 (en) 2023-09-07
MX2022005250A (es) 2022-06-08
ES3055126T3 (en) 2026-02-10
CN114728003B (zh) 2025-01-28

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)